Sandrine Delignat

Paris, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Fast Generation of F(Ab')2 Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

Fast Generation of F(Ab')2 Fragments From Human IgG Using Fc-Fused IgG-Degrading Enzyme.

Journal: European journal of immunology

Published: November 28, 2025

Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans.

Novel assays to assess the prevalence and neutralizing potential of anti-IdeS antibodies in healthy humans.

Journal: Frontiers in immunology

Published: October 20, 2025

Shaping T cell responses to factor VIII in hemophilia A with sialylated immunodominant peptides.

Shaping T cell responses to factor VIII in hemophilia A with sialylated immunodominant peptides.

Journal: Haematologica

Published: September 29, 2025

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 02, 2025

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.

Nanoparticles targeting liver sinusoidal endothelial cells improve tolerance to vector and transgene antigens through tolerance spreading.

Journal: Molecular therapy : the journal of the American Society of Gene Therapy

Published: September 02, 2025

Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides.

Regulation of immune responses to therapeutic factor VIII by transplacental delivery of Fc-fused immunodominant factor VIII domains or peptides.

Journal: Haematologica

Published: November 27, 2024

Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension.

Binding of therapeutic Fc-fused factor VIII to the neonatal Fc receptor at neutral pH associates with poor half-life extension.

Journal: Haematologica

Published: August 30, 2024

Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology.

Half-Life Extension of the IgG-Degrading Enzyme (IdeS) Using Fc-Fusion Technology.

Journal: European journal of immunology

Published: May 16, 2024

High factor VIII concentrations interfere with glycoprotein VI-mediated platelet activation in vitro.

High factor VIII concentrations interfere with glycoprotein VI-mediated platelet activation in vitro.

Journal: Journal of thrombosis and haemostasis : JTH

Published: September 15, 2023

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.

Imlifidase, a new option to optimize the management of patients with hemophilia A on emicizumab.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 26, 2023

Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy.

Transplacental delivery of therapeutic proteins by engineered immunoglobulin G: a step toward perinatal replacement therapy.

Journal: Journal of thrombosis and haemostasis : JTH

Published: January 01, 2023

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.

The IgG-degrading enzyme, Imlifidase, restores the therapeutic activity of FVIII in inhibitor-positive hemophilia A mice.

Journal: Haematologica

Published: August 05, 2022

Showing 1-12 of 43

Last Updated: 09/26/2026